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Abstract
Background: Conjugation of human and animal hemoglobins with polyethylene glycol has been widely explored
as a means to develop blood substitutes, a novel pharmaceutical class to be used in surgery or emergency
medicine. However, PEGylation of human hemoglobin led to products with significantly different oxygen binding
properties with respect to the unmodified tetramer and high NO dioxygenase reactivity, known causes of toxicity.
These recent findings call for the biotechnological development of stable, low-affinity PEGylated hemoglobins with
low NO dioxygenase reactivity.
Results: To investigate the effects of PEGylation on protein structure and function, we compared the PEGylation
products of human hemoglobin and Trematomus bernacchii hemoglobin, a natural variant endowed with a
remarkably low oxygen affinity and high tetramer stability. We show that extension arm facilitated PEGylation
chemistry based on the reaction of T. bernacchii hemoglobin with 2-iminothiolane and maleimido-functionalyzed
polyethylene glycol (MW 5000 Da) leads to a tetraPEGylated product, more homogeneous than the corresponding
derivative of human hemoglobin. PEGylated T. bernacchii hemoglobin largely retains the low affinity of the
unmodified tetramer, with a p50 50 times higher than PEGylated human hemoglobin. Moreover, it is still sensitive
to protons and the allosteric effector ATP, indicating the retention of allosteric regulation. It is also 10-fold less
reactive towards nitrogen monoxide than PEGylated human hemoglobin.
Conclusions: These results indicate that PEGylated hemoglobins, provided that a suitable starting hemoglobin
variant is chosen, can cover a wide range of oxygen-binding properties, potentially meeting the functional
requirements of blood substitutes in terms of oxygen affinity, tetramer stability and NO dioxygenase reactivity.
Background
Hemoglobin-based oxygen carriers (HBOCs) are a novel
therapeutic class consisting of hemoglobin (Hb) deriva-
tives administered intravenously as substitutes for blood
transfusions. Modifications of the natural tetramer are
required to reduce toxicity, as unmodified, cell-free Hb,
once dissociated into dimers, is easily filtered by the kid-
neys and causes severe nephrotoxicity. Moreover, Hb
extravasates through the endothelium, where it sca-
venges the vasoactive mediator nitrogen monoxide
(NO), causing a range of toxic effects that include
vasoconstriction and blood pressure increase. The stra-
tegies so far explored to avoid such effects mainly aim
at increasing the molecular size of the natural Hb tetra-
mers, thus limiting the size-dependent vessel extravasa-
tion and renal ultrafiltration. Beside some attempts at
designing recombinant Hbs with higher molecular
weight or lower dimer-tetramer dissociation constants
[1-5], most products proposed for clinical use consist of
Hb purified from whole blood and chemically modified
to achieve either intramolecular cross-linking or conju-
gation with polyethylene glycol (PEG) [6]. PEG derivati-
zation usually consists in the reaction between
maleimido-functionalized PEG (MAL-PEG) molecules
with either solvent-exposed cysteyl residues or thiol
groups introduced through the reaction of lysyl side
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chains with 2-iminothiolane (IMT) under either aerobic
[7] or anaerobic [8] conditions. PEG-decorated human
Hb (HbA) derivatives have been evaluated in several
clinical trials [9]. Adverse effects have so far prevented
their application as a replacement of red blood cells
[10].
One of the limits of HBOCs lies in the large differences
between their oxygen binding properties with those of
red blood cells. As a matter of fact, cell-free HbA cannot
bind the intra-erythrocyte allosteric effector 2,3-bispho-
sphoglycerate, which increases the P50 (the oxygen partial
pressure required to achieve half saturation) from 10
Torr to around 26 Torr at 37°C, pH 7.4. Moreover, free
Hb in the plasma is usually at concentrations low enough
to significantly dissociate into dimers, which do not show
cooperativity and exhibit a P50 close to that of R-state
Hb. PEGylation itself destabilizes the Hb tetramer and
shifts the tetramer-dimer equilibrium towards the latter,
with loss of cooperativity and a further increase in affinity
[11]. Particularly, the reaction of PEG with Cys b93, con-
served in 90% of vertebrates [12], was associated with tet-
ramer dissociation and increased affinity [11,13]. As a
matter of fact, both PEGylation of HbA in the T quatern-
ary state, where Cys b93 is not reactive [8] and the rever-
sible protection of Cys b93 HbA prior to conjugation
[14] result in higher tetramer stability and lower affinity.
However, based on experiments on HbA mutants, an
increase in oxygen affinity seems to be at least partially
independent of the derivatization of Cys b93 [15], sug-
gesting that PEGylation induces changes in the hydration
shell of hemoglobin, shifting the conformational equili-
brium towards the more hydrated R state, regardless of
the PEGylation sites.
In the light of the recent setbacks suffered by PEGy-
lated Hb in clinical trials [10], a deeper investigation of
the relationship between the oxygen-binding properties
and PEGylation in Hbs was undertaken. One of the possi-
ble strategies focused on the use of non-human PEGy-
lated Hbs, taking advantage of the low immunogenicity
of PEGylated proteins in general [16]. Non-human Hbs
might greatly differ in terms of PEGylation pattern, oxy-
gen-binding properties and sensitivity to allosteric effec-
tors. A product consisting of bovine Hb decorated with
10-12 units of 5000 Da-MW PEG was investigated as a
possible blood substitute and showed a P50 of 10.2 Torr
at 37°C [17], higher than that of PEGylated human Hb
but still far from that of human blood (around 26 Torr).
TetraPEGylated canine Hb [16] similarly showed a P50 of
10 Torr under the same conditions. In view of investigat-
ing the relationship between the oxygen affinity of animal
Hbs and that of their PEGylation products, Hbs from
Notothenioidei, the dominant suborder of teleosts in
Antarctica, are particularly interesting, as they show
peculiar features that make them potentially less sensitive
to the undesirable effects of PEGylation. The oxygen affi-
nity of these Hbs is exceptionally low [18], an evolution-
ary consequence of the high oxygen concentration in the
cold Antarctic waters. Moreover, unlike HbA, fish Hbs
show little or no dissociation of the tetramer into dimers,
even in the ligated form [19]. Finally, Cys b93, present in
the great majority of vertebrate Hbs and known to greatly
perturb the properties of PEGylated Hbs and to scavenge
NO [11], is missing in Hbs of almost all teleosts. The
remaining cysteyl residues are all buried inside the pro-
tein matrix [20], suggesting that PEG conjugation can be
carried out regardless of the quaternary or ligation state.
We therefore decorated Hb from Trematomus bernacchii
(TbHb) with PEG and characterized the reactivity with
oxygen and NO. The results were compared with those
obtained for PEGylated HbA.
Methods
Reagents
2-iminothiolane (IMT), HEPES buffer, ethylendiaminote-
traacetic acid (EDTA), phosphate buffered saline solu-
tion (PBS), sodium ascorbate, catalase and the reagents
for the Hayashi enzymatic reducing system [21] were
purchased from Sigma Chemical Co. (St. Louis, MO, U.
S.A.) and maleimido polyethylene glycol (MAL-PEG)
(5600 Da-MW) from Nektar Molecule Engineering
(Nektar Therapeutics, San Carlos, CA, U.S.A.). All other
reagents were of the best available commercial quality.
Collection of specimens and Hbs purification
Specimens of TbHb were collected by gill nets or hook-
and-line in the vicinity of Terra Nova Bay “Mario Zuc-
chelli” Station (74°42’S, 164°07’E), Ross Sea, Antarctica,
and kept in aquaria supplied with running, aerated sea
water. Blood was withdrawn with heparinised syringes
from the caudal vein. Hemolysates were prepared as
described previously [22]. Saline-washed erythrocytes
were frozen at -80°C until use. Purification of TbHb at
98% was carried out as described previously [23]. HbA
was purified as described elsewhere [24].
Cysteine titration
Preliminarily to PEGylation experiments, the reactivity
of the cysteyl residues of TbHb was evaluated in both
the deoxy- (T) and carboxy- (R) states using 4,4’dithio-
dipyridine (4-PDS) [25]. For the titration under anerobic
conditions, the protein solution was incubated under
helium flux until the absorption spectrum shifted to the
deoxy-Hb form. A separately deoxygenated stock solu-
tion of 4-PDS was anaerobically added.
Hbs PEGylation
The PEGylation reaction was carried out following the
protocol published for HbA in aerobic conditions
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[11,26]. Briefly, TbHb or HbA were treated in the pre-
sence of IMT (80 moles/tetramer moles) and then with
MAL-PEG 5600 Da-MW (12 moles/tetramer moles)
(Figure 1), at 10°C to prevent any heme oxidation dur-
ing the reaction. TbHb was treated in the presence of
CO, subsequently removed under oxygen flow before
measurements. The reactions of IMT and MAL-PEG
were quenched using lysine and cysteine in excess,
respectively. Less than 5% met-Hb was formed during
the reaction. To monitor the PEGylation reaction, small
aliquots of the reaction mixture were sampled every 10
minutes. The reaction was quenched by addition of
lysine and cysteine in excess. The samples were analyzed
by sodium dodecylsulfate/polyacrylamide gel electro-
phoresis (SDS-PAGE) and the electropherograms were
evaluated using the Quantity One software (Bio-Rad).
Under denaturing conditions, SDS-PAGE applied to
PEGylated Hbs was able to separate PEGylated Hb into
unmodified globin chains and globin chains with differ-
ent PEGylation degree [11]. To evaluate the
homogeneity of the final products, electrophoresis under
native conditions was carried out in 8-2% gradient gel
and analyzed as described elsewhere [27].
Determination of oxygen-binding curves
Oxygen-binding curves of HbA, TbHb and their PEGy-
lated derivatives, called PEG-Hboxy and PEGTbHb,
respectively, were measured with a modified tonometer
[24]. Before titration, the stock solutions of the proteins
were diluted in a solution containing 100 mM HEPES, 1
mM sodium EDTA, at either pH 7.0 or 8.0, to a final
concentration of 30 μM. Sodium ascorbate and catalase
were added to final concentrations of 5 mM and 103 U/
ml, respectively, to prevent significant autoxidation dur-
ing the measurement. For TbHb and PEGTbHb, experi-
ments were carried out in the presence and absence of
the allosteric effector ATP at a final concentration of 3
mM. For the experiments on TbHb and PEGTbHb
stored in the carbomonoxy form, CO was removed by
exposure to pure oxygen for 2 hours prior to titration,
taking advantage of the relatively low affinity of TbHb
for CO (data not shown). The samples where then
exposed to oxygen partial pressures ranging from 0 to
760 Torr generated using an Environics 4000 (Enviro-
nics inc, Tolland, CT, U.S.A.) gas mixer and pre-mixed
helium/oxygen bottles, at 10°C. Spectra were collected
in the 350-700 nm range using a Cary 4000 (Agilent
Technologies, Lexington, MA, U.S.A.) spectrophot-
ometer. The oxygen saturation at each partial oxygen
pressure was determined by deconvoluting the spectra
in the 450-700 nm range to a linear combination of the
reference spectra of deoxy-, oxy- and met-Hb, plus a
baseline. The deoxy reference spectra were obtained for
HbA and TbHb in the presence of sodium dithionite,
whereas reference spectra for the oxy forms were
obtained in pure oxygen in the presence of the Hayashi
reducing system [21]. The Hill’s coefficient (n) and P50
were calculated by linear regression of the Hill’s plots in
the saturation range 20-80%.
Flash photolysis experiments
The experimental set up has been described previously
[28,29]. Flash photolysis measurements were performed
using the circularly polarized second harmonic of a Q-
switched Nd:YAG laser (Surelite II Continuum) and a
cw Xe arc lamp as a monitoring beam. The transient
absorbance signals were measured at 436 nm with a 5-
stage photomultiplier.
NO dioxygenase activity
The rates of the NO dioxygenase reactivity at a single
NO concentration were determined for HbA, TbHb,
PEG-Hboxy and PEGTbHb by rapid mixing using a
stopped-flow apparatus (SX.18MV, Applied
Figure 1 Schematic representation of extention arm facilitated
PEGylation chemistry.
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Photophysics). The NO solutions were generated by
equilibrating a previously deoxygenated PBS solution at
pH 7.4 with a gas mixture of NO in nitrogen. The exact
concentration of NO was then measured by titration of
the solution with deoxygenated HbA under anaerobic
conditions and determined to be 12 μM. The protein
concentration was 3 μM. The reaction was monitored at
405 nm. Between 5 and 10 traces were collected and
averaged. All measurements were carried out under
strict anaerobic conditions at 20°C.
Results and Discussion
Cysteine reactivity
Sulfhydryl reactivity towards 4-PDS of carbomonoxy-
and deoxy- TbHb was very slow (data not shown) with
the fastest-reacting cysteine completing the reaction in
more than 24 hours. The slow reactivity of TbHb con-
firmed the structural data [20], which indicated the
absence of exposed cysteyl residues. 2-iminothiolane-
generated SH groups are therefore predicted to be the
only reactive sites towards MAL-PEG (Figure 1). For
comparison, HbA reacts with a twice equimolar amount
4-PDS within 10 minutes (data not shown) due to the
exposed Cys b93. It is therefore expected that TbHb,
unlike HbA, would not react directly with MAL-PEG.
PEGylation
Samples collected at different times of the PEGylation
reaction were compared in a SDS-PAGE gel (data not
shown) and analyzed by densitometry (Figure 2). The
reaction appeared to be completed in 30 minutes. The
densitometric analysis [11] showed that about four PEG
chains per tetramer are added during the reaction, as
compared to the 5-6 PEG chains/tetramer added to
HbA under the same reaction conditions. Nevertheless,
in native electrophoresis, PEGTbHb exhibited a slower
migration with respect to PEG-Hboxy, possibly due to
differences in electric charge (Figure 3). Some other
noticeable differences emerged with respect to PEG-
Hboxy. Particularly, the TbHb PEGylated derivative
appeared more homogeneous and did not show any
traces of unmodified tetramer (Figure 3), which were
consistently observed in all preparation of PEG-Hboxy
[27]. It is widely recognized that unmodified Hb is very
toxic, as it can extravasate and be filtered at glomerular
level. The complete derivatization of TbHb would there-
fore be a valuable property for a blood substitute.
Oxygen-binding properties
Oxygen affinity, cooperativity and the Bohr effect of
PEGylated Hb derivatives and unmodified Hbs were
measured under different conditions (Figure 4). The
oxygen-binding curves were determined at pH 7.0 and
pH 8.0, at 10°C. The analysis allows calculating P50 and
Hill coefficient values (Table 1). At pH 7.0, HbA exhib-
ited a P50 of 1.7 Torr, which decreased to approximately
0.4 Torr upon PEGylation (Table 1). The derivatization
also resulted in loss of cooperativity, with the Hill coeffi-
cient decreasing from around 2 to 1.2. TbHb, under the
same conditions, showed a much higher P50 of 28.2 ±
0.2 Torr. PEGylation resulted in an increase in oxygen
affinity to 19.7 ± 0.3 Torr. However, P50 remained 50-
fold higher than PEG-Hboxy under the same conditions.
Cooperativity was significantly reduced, with the Hill
coefficient decreasing from 2 to around 1.3. The
changes in oxygen-binding properties of TbHb upon
PEGylation are therefore similar to those observed for
PEG-Hboxy, in particular showing loss in cooperativity.
Considering the stability of the TbHb tetramer, this
effect is likely due to the steric effects of the PEG moi-
eties, which prevent the transition between the T and R
states, rather than the dissociation of the tetramer, as
seen in HbA. Despite the loss in cooperativity, the P50
of PEGTbHb remains remarkably high. Moreover, ATP
at saturating concentrations of 5 mM (data not shown)
still acts as an allosteric effector (Table 1), raising P50 to
31.1 Torr. These data, combined with those relative to
PEGylated Hbs of other species, particularly in bovine
[30] and canine Hbs [16], show that, regardless of their
different oxygen affinity, there is indeed a correlation
between the increase in affinity and the PEGylation
Figure 2 PEGylation reaction rates. Reaction time dependence of
PEG conjugation on globin subunits as determined from the
densitometric analysis of SDS-PAGE gels: 0 PEG bound per subunit
(open circles), one PEG bound per subunit (open inverted triangles),
two PEG bound per subunit (open squares), three PEG bound per
subunit (open diamonds), four PEG bound per subunit (open
triangles).
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reaction. The non-specific effect of PEGylation in
increasing the oxygen affinity was also demonstrated
within the same preparation, through the electrophoretic
separation of differently PEGylated HbA derivatives hav-
ing different affinities [27].
Flash photolysis experiments
The CO rebinding kinetics measured after laser flash
photolysis on the carbomonoxy forms of HbA and
TbHb in the absence and presence of PEGylation is
reported in Figure 5. The rebinding traces were con-
verted to fraction N(t) of deoxy-Hb as a function of
time. Dependence of the kinetics on the CO concentra-
tion allows distinguishing between unimolecular and
bimolecular processes (data not shown). As it is well
established for HbA, CO rebinding comprises multiple
phases: a nanosecond (unimolecular) geminate process
due to rebinding from within the heme pocket or the
protein matrix, and two second order processes, one in
the microsecond time scale, ascribed to bimolecular
rebinding to quaternary R state, and one in the millise-
cond time scale, ascribed to the bimolecular rebinding
to proteins that have switched to quaternary T state
[31]. In order to reproduce the experimental rebinding
curves for HbA, we used a sum of six exponential
decays functions, as proposed by Kliger and coworkers
[32]. In Figure 5 we also show the results of the global
fitting on HbA and TbHb (both with and without PEGy-
lation), demonstrating a very good agreement between
calculated and experimental curves. Besides the two
exponential decays which are necessary for describing
the geminate phase (10 and 182 ns for HbA; 14 and 452
ns for TbHb), we detected two processes ascribed to
quaternary relaxation from the R to the T states in the
micro-millisecond time scale (1 and 140 μs for HbA;
110 μs and 1.5 ms for TbHb), one phase associated with
the rebinding to R state (350 μs for HbA; 7 ms for
Figure 3 Size distribution of derivatized hemoglobins. Gradient
native PAGE of HbA, TbHb and their PEGylated derivatives.
Figure 4 Oxygen binding properties of derivatized
hemoglobins. Hill plots of oxygen-binding curves of HbA (closed
squares), TbHb (closed circles) and PEGTbHb (open circles),
measured in 100 mM HEPES 1 mM EDTA, 5 mM sodium ascorbate,
103 U/ml catalase, pH 7.0, at 10°C. Experimental points are fitted to
the Hill equation, with calculated Hill’s coefficients and P50’s
reported in Table 1.
Table 1 Oxygen binding parameters of human and T.
bernacchii Hbs and their PEGylated derivatives
pH 7.0 pH 8.0
Protein P50 n P50 n
HbA 1.7 ± 0.1 2.05 ± 0.02 0.39 ± 0.3 1.72 ± 0.03
PEG-Hboxy 0.4 [35] 1.2 [36]
TbHb 28.2 ± 0.2 2.06 ± 0.01 7.3 ± 0.1 1.75 ± 0.03
PEGTbHb 19.7 ± 0.3 1.33 ± 0.02 5.3 ± 0.1 1.09 ± 0.02
PEGTbHb + ATP 31.1 ± 0.2 1.09 ± 0.01 4.4 ± 0.3 1.02 ± 0.03
Measurements were made in 100 mM HEPES, 1 mM EDTA, 5 mM ascorbate,
103 U/ml catalase, at 10°C. The values for PEG-Hboxy were calculated from
published data taking into account the temperature dependence of the
oxygen binding parameters.
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TbHb) and one phase associated with the rebinding to T
state (7 ms for HbA; 21 ms for TbHb). As previously
shown in HbA [11], while PEGylation preserves the gen-
eral features of the dynamics and reactivity of the pro-
tein, it partially prevents the R to T relaxation, so that
upon PEGylation the fractional amplitude of the rebind-
ing to R changes from about 27% to 80% in HbA and
from 34% to 76% in TbHb.
NO dioxygenase activity
The scavenging of NO, associated with an extremely
rapid dioxygenation reaction with oxy-Hb to form met-
Hb and inert nitrate, is significant when Hb is present
in blood vessels outside erythrocytes and is likely to be
the main determinant of the adverse effects of HBOCs
[33,34]. In order to develop a possible blood substitute,
it is crucial to consider not only oxygen-transport prop-
erties of these Hbs, but also the influence that these
products can have on NO homeostasis. The reaction
rates of the NO with unmodified TbHb and its PEGy-
lated Hb derivatives were measured and compared with
those of HbA and its PEGylation product. Analysis of
the oxidation kinetics of oxy TbHb treated with NO
(Figure 6) yields a kobs of 7.2 μM
-1s-1, indicating slower
reactivity with respect to HbA, with a kobs of 64 μM
-1s-1
under the same experimental conditions, in agreement
with literature data [34]. PEGylation of TbHb seems to
only marginally affect the NO dioxygenase reactivity,
with a kobs for PEGTbHb of 7.7 μM
-1s-1. A comparable
decrease in the NO dioxygenase activity of HbA was
achieved by mutating residues aE11, bE11, and bB10 (2-
15 μM-1s-1) [33]. These mutants showed reduced in vivo
vasoactivity, directly correlated with the in vitro NO
oxygenation rate. The same pattern is observed in HbA,
the PEGylation of which, under aerobic and anaerobic
conditions, yields kobs of 83 μM
-1s-1 (Figure 6) and 86
μM-1s-1 (data not shown), respectively.
Conclusions
The functional characterization of the PEG-conjugated
derivative of the highly stable Hb tetramer of T. bernac-
chii confirms the non-specific effects of PEGylation
already observed in human, bovine and canine Hbs,
including an increase in oxygen affinity, a decrease in
cooperativity and a reduction of the R- to T-quaternary
switching upon flash photolysis. However, these non-
specific effects are accompanied by the partial retention
of the remarkably low affinity for oxygen, the sensitivity
to allosteric effectors and the low NO dioxygenase reac-
tivity. These results indicate that PEGylated Hbs, pro-
vided that a suitable starting Hb variant is chosen, can
cover a wide range of oxygen-binding properties,
Figure 5 CO rebinding properties of derivatized hemoglobins.
Effect of PEGylation on CO rebinding to HbA and TbHb and their
PEGylated derivatives. The time courses of the deoxyheme fraction
are shown for HbA (gray circles), PEG-Hboxy (black circles), TbHb
(gray solid line) and PEGTbHb (black solid line), in 100 mM HEPES, 1
mM sodium EDTA, 1 atm CO, pH 7.0 at 10°C. Data were fitted as
reported in Materials and Methods. The fitting curves are shown in
red.
Figure 6 NO dioxygenase reactivity. Determination of the effect
of PEGylation on NO dioxygenase reactivity of HbA and TbHb and
their PEGylated derivatives. The reaction was carried out by rapid
mixing under anaerobic conditions at 20°C. 3 μM oxygenated HbA
(gray dotted line), TbHb (gray solid line), PEG-Hboxy (black dotted
line), and PEGTbHb (black solid line), with a deoxygenated PBS
solution containing 12 μM NO. The reaction was monitored at 405
nm and absorbance differences were normalized.
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potentially meeting the functional requirements of blood
substitutes.
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